TBHQ (tert-Butylhydroquinone) |
| Catalog No.GC34057 |
TBHQ (tert-Butylhydroquinone) (tert-Butylhydroquinone) es un activador de Nrf2 ampliamente utilizado, protege contra la cardiotoxicidad inducida por doxorrubicina (DOX) a través de la activaciÓn de Nrf2. TBHQ (tert-butilhidroquinona) (tert-butilhidroquinona) también es un activador de ERK; rescata la inhibiciÓn de la proliferaciÓn celular inducida por dehidrocoridalina (DHC) en el melanoma.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1948-33-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
TBHQ is an antioxidant that activates Nrf2.
[1]. Sukumari-Ramesh S et al. Post-Injury Administration of Tert-butylhydroquinone Attenuates Acute Neurological Injury After Intracerebral Hemorrhage in Mice. J Mol Neurosci. 2016 Apr;58(4):525-31. [2]. Tert-butylhydroquinone ameliorates doxorubicin-induced cardiotoxicity by activating Nrf2 and inducing the expression of its target genes
Average Rating: 5 (Based on Reviews and 6 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *